Late-Breaking Data

December 2022, Vol 3, No 4 — December 22, 2022
Although HER2 alterations have been reported in up to 20% of biliary tract cancers (BTCs), no HER2-targeted therapies are currently approved for the treatment of BTC.
Read More

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: